SS&C Technologies Holdings Inc Q4 2024 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Jeff Schmitt - William Blair & Company - Analyst : Hi. Good afternoon. In the Healthcare business, clearly the tailwind is gone but could you provide us with more details on client wins in the quarter? And how does the pipeline look for '25?

Question: Jeff Schmitt - William Blair & Company - Analyst : That's right. Headwind. I'm sorry.

Question: Jeff Schmitt - William Blair & Company - Analyst : Great. And then, could you provide us with an update on the cross-selling efforts with Battea? And how big do you think that revenue opportunity could be?

Question: Jeff Schmitt - William Blair & Company - Analyst : Great. Thank you.

Question: Alexei Gogolev - JPMorgan Chase & Co. - Analyst : Hello, everyone. Hi, Bill. Three months ago, when you provided us with the fourth-quarter guidance, expectations for organic growth at the midpoint was below 3%. And you delivered around 7% organic. Sounds like, based on what you said in the prepared remarks, there were some deals that slipped from 3Q into 4Q. But I was wondering if there were any other surprises in the quarter, maybe better demand environment or perhaps some deals that closed earlier than expected?

Question: Alexei Gogolev - JPMorgan Chase & Co. - Analyst : Perfect. Thank you, Bill. And also, directionally, have you had a chance to maybe consider within the team -- with Rahul and with the rest of the team -- around the recent decision by the European Commission to cut the corporate reporting requirements by almost 25%. Do you view regulation or deregulation as a risk to your regulatory business or filing business? And what long term you do have for where the industry is heading?

Question: Alexei Gogolev - JPMorgan Chase & Co. - Analyst : Makes a lot of sense. Thank you, Bill.

Question: Daniel Perlin - RBC Dominion Securities Inc. - Analyst : Thanks. Good evening and congrats on a good quarter. And, obviously, on your new grandchild. I wanted to spend a moment, if I could, just in terms of thinking through the investment cycle. You've invested a lot in products and solutions over the past 12 to 18 months and that's obviously starting to play out in the organic growth. I'm trying to understand the building blocks that you have for the 5% organic growth, at the midpoint, for 25%. I know Healthcare turned positive and like you said, there's some lumpiness to the license deals. But it seems like it's going to be just a lot more sustainable at those levels. And I just want to get your thoughts on what your view is there and maybe the key components to that.

Question: Daniel Perlin - RBC Dominion Securities Inc. - Analyst : Totally see the results. So one other quick thing, if I could. Bill, I've heard you at conferences also speak about the superannuation opportunity in Australia and you've got this lift-out. Would you mind just, maybe, spending just a minute level-setting what you think of that market? How big it could be? I know you said you got 5% market share so there's a huge opportunity. But I'm just not as familiar with who the major players are there and what that competitive dynamic is and therefore, what your real opportunity is. Thank you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 06, 2025 / 10:00PM, SSNC.OQ - Q4 2024 SS&C Technologies Holdings Inc Earnings Call

Question: Daniel Perlin - RBC Dominion Securities Inc. - Analyst : Excellent.

Question: Peter Heckmann - D.A. Davidson & Co. - Analyst : Hey. Good afternoon, everyone. Sorry, someone poked their head in so I hope someone hasn't already asked my question. But in Insignia Financial, can you talk about that deal a little bit? Whether you've included anything in your 2025 guidance. And then, if you could, maybe, size it a little bit in terms of what should we be thinking about, in terms of an annual revenue contribution?

Question: Peter Heckmann - D.A. Davidson & Co. - Analyst : Okay. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 06, 2025 / 10:00PM, SSNC.OQ - Q4 2024 SS&C Technologies Holdings Inc Earnings Call And then, just in terms of this most recent acquisition, FPS Trust. I didn't ping [Brian] yet. I hadn't got any ideas in terms of like sizing your price. Now, would you characterize that as a relatively small tuck-in deal or something a bit bigger?

Question: Peter Heckmann - D.A. Davidson & Co. - Analyst : Got it. Thank you.

Question: Kevin McVeigh - UBS Securities LLC - Analyst : Great. Thanks so much. And let me add my congratulations to you as well, Bill, on your grandson. If the midpoint of 2025 is 5%, what would be the low end of that, organically? And what would be the high end of that? Any kind of factors as to what gets to the low end as opposed to the high end?

Question: Kevin McVeigh - UBS Securities LLC - Analyst : Super helpful. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 06, 2025 / 10:00PM, SSNC.OQ - Q4 2024 SS&C Technologies Holdings Inc Earnings Call And then, just real quick, obviously, the Healthcare business looks terrific. It sounds like that there was some software sales. Is that a pretty good proxy? Like, is there any type of leading indicator that leads to, maybe, larger contracts or if you think about (inaudible), going into 26, or is that independent?

Question: Kevin McVeigh - UBS Securities LLC - Analyst : Makes a lot of sense. Congratulations on that. Just really terrific results.

Question: Andrew Schmidt - Citigroup Inc. - Analyst : Hey, guys. Thanks for taking my questions. And congrats on the organic growth here. It's great to see. Maybe just dig in to GlobeOp for a second. Nice to see the acceleration there. Maybe we could just unpack the drivers this quarter, over the past few quarters, across private markets, hedge funds, real assets, any call-outs in terms of the growth drivers and obviously, middle and back office, where the opportunities are? Thanks, guys.

Question: Andrew Schmidt - Citigroup Inc. - Analyst : That's great to hear. I appreciate that. And then, maybe, just two other questions -- separate areas. I'll ask them up front. GlobeOp. How to think about the range of outcomes for '25 in terms of banking? And then, just separately, obviously, Automation continues to be a big opportunity for you, guys. Maybe, give us an update in terms of where you're at, in terms of automating key functions. And I know some of that is reinvesting in products, et cetera. But where we're at in terms of that initiative. Thanks a lot, guys. Really appreciate it.

Question: Andrew Schmidt - Citigroup Inc. - Analyst : Got it. Thanks so much, Bill. And then, just on the Automation side? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. FEBRUARY 06, 2025 / 10:00PM, SSNC.OQ - Q4 2024 SS&C Technologies Holdings Inc Earnings Call

Question: Andrew Schmidt - Citigroup Inc. - Analyst : Got it. Thanks so much, Bill.